Latest Headlines

  1. GV20 Therapeutics Announces Collaboration Agreement With Mitsubishi Tanabe Pharma Corporation To Develop Novel Antibody-Drug Conjugates 3/26/2025

    GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC).

  2. A Breakthrough Moment: Mcmaster Researchers Discover New Class Of Antibiotics 3/26/2025

    The last time a new class of antibiotics reached the market was nearly three decades ago — but that could soon change, thanks to a discovery by researchers at McMaster University.

  3. Redwire Awarded NASA Contract To Expand Pharmaceutical Drug Development In Space For Future Commercialization 3/25/2025

    Redwire Corporation, a leader in space infrastructure for the next-generation space economy, has been awarded a NASA contract to launch four additional pharmaceutical drug investigations to the International Space Station using the company’s innovative Pharmaceutical In-space Laboratory (PIL-BOX).

  4. SOLVE FSHD Announces Strategic Collaboration With Transcripta Bio To Advance Drug Discovery For FSHD 3/25/2025

    SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company.

  5. Predictive Oncology Successfully Develops Predictive Models Derived From Never-Before-Seen Compounds For Prevalent Cancer Indications Including Breast, Colon And Ovary 3/25/2025

    Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute.

  6. Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation For Obesity Due To Leptin Receptor Deficiency 3/25/2025

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition.

  7. ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation For RCT2100 For The Treatment Of Cystic Fibrosis 3/25/2025

    ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT2100, a novel, investigational mRNA therapy being developed to treat cystic fibrosis (CF).

  8. Charles River And Valo Health Identify A Potential Therapeutic For Lupus Using Logica, An AI-Powered Drug Discovery Platform 3/25/2025

    Charles River Laboratories International, Inc. and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need.

  9. FDA Approves New Prostate Cancer Imaging Agent Gozellix® 3/21/2025

    Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging agent for prostate cancer.

  10. HiRO And Hallym University Sacred Heart Hospital Sign Strategic MOU To Advance Drug Development 3/19/2025

    Harvest Integrated Research Organization (HiRO), a boutique global CRO, is pleased to announce the signing of a Memorandum of Understanding (MOU) with Hallym University Sacred Heart Hospital in Seoul, South Korea.